Drug news
Regeneron files Eylea(VEGF TRAP-EYE) at FDA for CRVO
Based on the results of the GALILEO study and one otherstudy Regeneron Pharmaceuticals, has submitted a supplemental Biologics License Application (sBLA) in the US for the CRVO indication and has been granted an FDA action date of 23 September 2012.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.